CD25+CD27+CD70− alloantigen-specific Tregs: promising stable immunotherapy for transplantation - Takeaways - MDSpire

CD25+CD27+CD70− alloantigen-specific Tregs: promising stable immunotherapy for transplantation

  • By

  • Arimelek Cortés-Hernández

  • Saúl Arteaga-Cruz

  • Iyari I. Martínez Iturbe

  • Katya Rosas-Cortina

  • Marco A. Vigil Mora

  • Erick Legorreta-Anguiano

  • Judith E. Reyes Barrientos

  • Evelyn K. Álvarez-Salazar

  • Alejandra Cervera

  • Beatriz E. Sánchez-Hernández

  • Armando Gamboa Domínguez

  • Gloria Soldevila

  • June 10, 2026

  • 0 min

Share

  • 1

    A novel strategy was developed to isolate and expand CD25+CD27+CD70− alloantigen-specific Tregs for improved immunotherapy in transplantation.

  • 2

    The protocol achieved a 434-fold expansion of Tregs with over 95% purity while maintaining significant FOXP3-TSDR demethylation.

  • 3

    Expanded CD27+ AS-Tregs displayed a strong immunoregulatory phenotype and effectively suppressed T cell proliferation in an antigen-specific manner.

  • 4

    These Tregs exhibited resilience to inflammatory cytokines and maintained lineage fidelity by not producing pro-inflammatory cytokines.

  • 5

    The findings suggest that CD27+ AS-Tregs are promising candidates for stable, long-term Treg therapy to enhance transplant tolerance.

Original Source(s)

Related Content